Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Spirea logo — Elevating the Therapeutic Potential of ADCs in Cancer and Be...

Spirea

Elevating the Therapeutic Potential of ADCs in Cancer and Beyond with Our Unique Multivalent ELIVATE Linker Technology

Founded 2017 United Kingdom Cambridge, United Kingdom 8 employees Seed Total: $2.40M Biotechnology, Health Care +1

General Information

Company Name Spirea
Founded Year 2017
Location United Kingdom Cambridge, United Kingdom
Employees 8
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Seed
Business Model B2B, Platform, API
Revenue Model Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Spirea. To contact Spirea, visit spirea.co.uk.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Spirea

Spirea, founded in 2017, is an innovative player in the Biotechnology, Health Care, and Pharmaceutical industries, headquartered in the United Kingdom. Emphasizing its slogan, "Elevating the Therapeutic Potential of ADCs in Cancer and Beyond with Our Unique Multivalent ELIVATE Linker Technology," Spirea is pioneering advancements in antibody-drug conjugates (ADCs).

The company is transforming cancer treatment through its proprietary ELIVATE technology, which enhances payload diversity for ADCs, optimizing therapeutic precision and pharmacokinetics. Spirea is advancing its ADC pipeline with a focus on strategic partnerships to maximize technology impact.

Recently, Spirea secured a £2.40M seed investment on 01 June 2022, with funding from prominent investors including ACF Investors, Cambridge Angels, Cambridge Enterprise, Syndicate Room, o2h Ventures, Jonathan Milner, and R42 Group, signaling strong investor confidence in its potential.

Taxonomy: Antibody-Drug Conjugates, Therapeutic Innovation, Drug Delivery Technology, Pharmacokinetics Optimization, Targeted Therapies, Oncology Treatments, Multivalent Linker Technology, Polymer Platform, Clinical Drug Development, Precision Medicine, Therapeutic Payload Expansion, Strategic Partnerships, Pipeline Development

Services & Products

Development of next-generation ADCs
ADC linker technology application
Collaborative ADC development

Target Customers

ADC oncology companies Small molecule oncology companies Degrader/molecule glue oncology companies Antibody therapeutics companies Inflammation and autoimmunity firms

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Seed £2.40M 7
ACF Investors Cambridge Angels Cambridge Enterprise
ACF Investors, Cambridge Angels +5
01 Jun 2022
Seed Undisclosed 1
o2h Ventures
o2h Ventures
01 Jan 2021
Seed Undisclosed 1
Start Codon
Start Codon
01 Jul 2020
Spinout Undisclosed 1
The University of Cambridge
The University of Cambridge
01 Jan 2017

Spirea Alternatives & Competitors

View All Alternatives
Spirea vs
Araris Biotech AG
Araris Biotech AG Switzerland

Building tomorrow's antibody-drug conjugates (ADCs)

Grant
23 employees
Biotechnology, Health Care
Spirea vs
Mersana Therapeutics
Mersana Therapeutics United States

Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fi...

Acquired
159 employees
Biotechnology, Health Care
Spirea vs
ONA Therapeutics
ONA Therapeutics Spain

First-in-class ADCs tailored to attack advanced cancer

Series A
35 employees
Biotechnology, Health Care
View all alternatives

FAQ About Spirea

Elevating the Therapeutic Potential of ADCs in Cancer and Beyond with Our Unique Multivalent ELIVATE Linker Technology
Spirea was founded in 2017.
Spirea is headquartered in Cambridge, United Kingdom.
Spirea operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Antibody-Drug Conjugates, Therapeutic Innovation, Drug Delivery Technology and Pharmacokinetics Optimization. Its customers include ADC oncology companies, Small molecule oncology companies and Degrader/molecule glue oncology companies.
Spirea has a B2B, Platform and API business model. Its revenue comes from Licensing and Service Fee.
Spirea has approximately 8 employees.
Spirea has completed 4 funding rounds, raising a total of $2.40M. The latest funding stage is Seed.
Spirea offers: Development of next-generation ADCs, ADC linker technology application, Collaborative ADC development.
Top alternatives and competitors to Spirea include Araris Biotech AG, Mersana Therapeutics, ONA Therapeutics, Antikor Biopharma Ltd, Tagworks Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Spirea and Araris Biotech AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Spirea, https://bouncewatch.com/company/spirea, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes